^
    Back
    Association details:
    Biomarker:ELTD1 expression
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

    Published date:
    04/24/2020
    Excerpt:
    Our results identify tumor vessel ELTD1 expression as a positive predictive marker for sunitinib-treatment in patients suffering from mRCC.
    DOI:
    10.1186/s12885-020-06770-z